Bettina Platt, PhD, FSB

Medicine & Life Sciences

1. Alzheimer Disease 100%
2. Cholinergic Agents 56%
3. Spatial Learning 50%
4. Electroencephalography 49%
5. Sleep 46%
6. Amyloid 42%
7. Cannabidiol 40%
8. Brain 37%
9. Phenotype 33%
10. Neurons 32%
11. Amyloid beta-Protein Precursor 31%
12. Memory 30%
13. Aluminum 26%
14. Learning 25%
15. Frontotemporal Dementia 25%
16. Pathology 24%
17. Spatial Memory 23%
18. Hippocampus 23%
19. Endocannabinoids 21%
20. Scopolamine 21%
21. Cannabinoids 21%
22. N-Methylaspartate 21%
23. Cognitive Dysfunction 20%
24. Non-Receptor Type 1 Protein Tyrosine Phosphatase 19%
25. Neuronal Plasticity 19%
26. Phosphorylation 18%
27. Cannabinoid Receptor CB1 18%
28. Fenretinide 17%
29. AM 251 17%
30. Neurodegenerative Diseases 16%
31. Wakefulness 16%
32. Memantine 15%
33. Neuroglia 14%
34. Dronabinol 14%
35. 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl) 4-methoxyphenyl methanone 14%
36. Short-Term Memory 14%
37. Synaptic Transmission 14%
38. Homeostasis 14%
39. tetrahydrocannabivarin 9 14%
40. poly-APS 14%
41. Long-Term Potentiation 14%
42. Tauopathies 13%
43. Calcium Signaling 13%
44. N-(3-(2-amino-4a,5,7,7a-tetrahydro-4H-furo(3,4-d)(1,3)thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide 13%
45. Neurosciences 13%
46. Insulin Resistance 13%
47. Interpersonal Relations 13%
48. REM Sleep 12%
49. Cannabis 12%